In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $5.00. The company's shares closed last Thursday at $0.85, close to its 52-week low of $0.53. According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -11.0% and a 32.5% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $2.70 average price target.
https://www.tipranks.com/news/blurbs/jmp-securities-thinks-proqrs-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more ProQR Therapeutics NV Charts.
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more ProQR Therapeutics NV Charts.